Download PDF
CC BY 4.0 · Pharmaceutical Fronts 2021; 03(02): e50-e55
DOI: 10.1055/s-0041-1735144
Original Article

Efficient Synthesis and Docking Analysis of Selective CDK9 Inhibitor NVP-2

Abdusaid Saidahmatov‡   #
1   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China
,
Xue-Wu Liang‡   #
1   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China
,
Yu-Qiang Shi
1   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China
,
Xu Han
1   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China
,
Hong Liu
1   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China
› Author Affiliations Funding This work was supported by the National Natural Science Foundation of China (Grant No. 21907102).
› Further Information
   Permissions and Reprints


Abstract

Graphical Abstract

NVP-2 (1), a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9), showed potent antitumor activity in preclinical studies. In this work, we designed and adopted a convergent synthetic route to efficiently synthesize NVP-2 (1). The key intermediate (7) was synthesized from malononitrile (2) and 1-bromo-2-(2-bromoethoxy)ethane (3) by successive cyclization, reduction, nucleophilic substitution with 2-bromo-6-fluoropyridine, and Suzuki–Miyaura reaction with (5-chloro-2-fluoropyridin-4-yl)boronic acid. Another key intermediate (11) was synthesized from (S)-1-methoxypropan-2-ol (8) by reaction with TsCl, electrophilic substitution reaction with tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate, and then by deprotection of Boc. Finally, a substitution reaction by the key intermediates (7) and (11) to afford the target product NVP-2 (1). The reaction conditions of the whole synthesis process were simple and mild, free of harsh conditions such as the microwave reaction and dangerous reagents in the original patent, and realized the efficient synthesis of NVP-2. In addition, we analyzed the binding mode of NVP-2 in the active pocket of CDK9 to provide reasonable design ideas for subsequent discovery of novel CDK9 inhibitors.

Keywords

NVP-2 - CDK9 inhibitor - efficient synthesis - docking analysis

# These authors contributed equally to this work.




Publication History

Received: 08 June 2021

Accepted: 07 July 2021

Article published online:
02 September 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24 (11) 1770-1783
    CrossrefPubMedGoogle Scholar
  • 2 Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov 2020; 10 (03) 351-370
    CrossrefPubMedGoogle Scholar
  • 3 Franco LC, Morales F, Boffo S, Giordano A. CDK9: a key player in cancer and other diseases. J Cell Biochem 2018; 119 (02) 1273-1284
    CrossrefPubMedGoogle Scholar
  • 4 Zhang H, Pandey S, Travers M. et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell 2018; 175 (05) 1244.e26-1258.e26
    CrossrefPubMedGoogle Scholar
  • 5 Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14 (02) 130-146
    CrossrefPubMedGoogle Scholar
  • 6 Wu T, Qin Z, Tian Y. et al. Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update. J Med Chem 2020; 63 (22) 13228-13257
    CrossrefPubMedGoogle Scholar
  • 7 Cho BC, Dy GK, Govindan R. et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer 2018; 123: 14-21
    CrossrefPubMedGoogle Scholar
  • 8 Mita MM, Joy AA, Mita A. et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014; 14 (03) 169-176
    CrossrefPubMedGoogle Scholar
  • 9 Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26 (01) 59-65
    CrossrefPubMedGoogle Scholar
  • 10 Cidado J, Shen M, Grondine M. et al. Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Cancer Res 2016; 76 (14) 3572
    CrossrefPubMedGoogle Scholar
  • 11 Winter GE, Mayer A, Buckley DL. et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol Cell 2017; 67 (01) 5.e19-18.e19
    CrossrefPubMedGoogle Scholar
  • 12 Olson CM, Jiang B, Erb MA. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 2018; 14 (02) 163-170
    CrossrefPubMedGoogle Scholar
  • 13 Barsanti PA, Hu C, Jin J. et al. Heteroaryl compounds and their uses. U.S. Patent 8415381B2. April, 2013
    Google Scholar